The 6th Annual World Congress on the Insulin Resistance Syndrome by Bloomgarden, Zachary T.
The 6th Annual World Congress on the
Insulin Resistance Syndrome
ZACHARY T. BLOOMGARDEN, MD
T
his is the ﬁrst of a series of articles
based on presentations at the 6th
Annual World Congress on the In-
sulin Resistance Syndrome held 25–27
September 2008 in Los Angeles,
California.
Yehuda Handelsman (Tarzana, CA),
the organizer and prime mover of the In-
ternational Committee for Insulin Resis-
tance, discussed clinical implications of
insulin resistance, touching on its rela-
tionship to sleep disorders, and the cyto-
kines produced by adipocytes. Reducing
adiposity appears to be an optimal ap-
proach to treatment of insulin resistance,
withexcessadiposetissueplayingrolesin
genesis of nonalcoholic steatohepatitis
(NASH), hyperuricemia, the polycystic
ovary syndrome, atherosclerosis, and di-
abetes. There are 57 million people in
the U.S. and 314 million overall in the
world with pre-diabetes, with conversion
to diabetes directly related to insulin re-
sistance, particularly in the setting of de-
creased insulin secretion. “Treating
diabetes works,” he commented, noting
the recent UKPDS (United Kingdom Pro-
spectiveDiabetesStudy)follow-upstudy,
and asked whether one should therefore
treat pre-diabetes, given the strong simi-
larities in risk for diabetes and cardiovas-
cular disease (CVD), further suggesting
that metabolic syndrome should be con-
sidered a pre-diabetes equivalent. Treat-
ment of pre-diabetes may beneﬁt from
lifestyle intervention, with consideration
ofpharmacologicaltreatmentinhigh-risk
patients, including thiazolidinediones,
metformin, and -glucosidase inhibitors;
such patients should have aggressive ef-
forts directed to CVD prevention with
blood pressure and LDL cholesterol goals
of 130/80 mmHg and 100 mg/dl,
respectively.
Cellular mechanisms of insulin
resistance
Ira Goldﬁne (San Francisco, CA) dis-
cussed the importance of plasma cell
membrane glycoprotein-1 (PC-1), also
termed ectonucleotide pyrophosphatase/
phosphodiesterase 1 (ENPP1), in insulin
resistance. PC-1 is an integral membrane
protein that plays an enzymatic role in
pyrophosphate and bone metabolism
and, separately, contains a domain that
binds to the insulin receptor. PC-1 over-
expression decreases insulin action in tis-
sue culture, and measurement of PC-1
content in ﬁbroblasts from insulin-
sensitive and -resistant individuals shows
the latter to have either elevated levels of
PC-1 or the Q-allele of PC-1, which is
associated with greater binding afﬁnity.
PC-1 content of adipose tissue and of
skeletal muscle similarly inversely corre-
lates with insulin sensitivity. PC-1 inhib-
its the insulin receptor by blocking the
connecting domain in the receptor’s
-subunit, which transmits insulin-
induced conformational change. When
insulin attaches to its receptor, the con-
formational change brings the receptor’s
-subunits together and leads to their
transphosphorylation, initiating insulin
action (1). PC-1 blocks the movement of
the -subunits, blocking then both the
insulin receptor substrate and SHC/SOS/
MAPK systems; PC-1 is speciﬁc for insu-
lin action and does not inhibit IGF-1
signaling.Intransgenicmiceoverexpress-
ing PC-1, with activity at a level compa-
rable with that in humans with insulin
resistance,hyperglycemiaandhyperinsu-
linemia occur, with decreased insulin-
mediated glucose uptake in muscle and
brain, perhaps explaining certain features
of insulin-resistant states. PC-1 is in-
creased in muscle of obese humans, cor-
relating with BMI, and in animal models
of obesity.
The Q-allele of the K121Q polymor-
phismoftheglycoproteinPC-1genehasa
lysine-to-glutamate substitution, exhibit-
ing two- to threefold greater binding to
the insulin receptor and thus decreasing
insulin receptor function for a given level
of PC-1 expression. PC-1 Q-allele fre-
quencyisincreasedinsome(2)butnotall
(3)insulin-resistantindividuals,aswellas
in those with type 2 diabetes, obesity,
polycystic ovary syndrome, and CVD,
with evidence that diabetes risk doubles
in subjects with two Q-alleles. PC-1 can
be measured in circulating monocytes,
lymphocytes, and plasma, appearing to
be shed from cells and not interacting
with the insulin receptor. Therapies may
be developed to lower PC-1, and studies
of monoclonal antibodies, antisense oli-
gomers, and siRNA are ongoing. Mono-
clonal antibody treatment reduces




receptor, which may be developed for
oraladministration,actingtorecruitinsu-
lin receptors to the cell surface and in tis-
sue culture increasing insulin sensitivity
in hepatocytes overexpressing PC-1.
Gerald Shulman (New Haven, CT)
discussed cellular mechanisms of insulin
resistance and pointed out that in 2030,
366 million people worldwide will have
diabetes,withprojecteddoublingofprev-
alence in Asia. Understanding cellular
mechanisms will allow development of
new targets for treatment. There is evi-
dence of decreased hepatic glucose up-
take, for which potential rate-controlling
steps are GLUT4, hexokinase, and glyco-
gen synthase, the former appearing to be
rate controlling, which led Shulman to
think that glycogen synthase activators
areunlikelytoimproveﬂuxintoglycogen
in skeletal muscle. He showed the effects
of increased free fatty acids (FFAs) reduc-
ing muscle glucose uptake. The Randle
hypothesis posits that this is due to accu-
mulation of glucose-6-posphate in the
myocyte because of competition for its
metabolism, but Shulman noted studies
of effects of increased FFA with intracel-
lular glucose-6-posphate levels and intra-
cellular glucose decreasing, suggesting
interference with GLUT4 in muscle and
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intracellular diacylglycerol (DAG), acting
via protein kinase C (PKC)- to increase
insulin receptor substrate-1 serine phos-
phorylation and to decrease tyrosine
phosphorylation,reducinginsulinaction.
Acetyl-CoA carboxylase appears to be in-
volved in this process, leading to reduced
mitochondrial oxidation, with FFA-
induced insulin resistance in muscle also
involving DAG acting via PKCε . Shulman
suggested that this pathway is involved in
hepatic steatosis, with weight loss pre-
sumably reducing intracellular DAG; cy-
tokine abnormalities did not appear to be
major mediators in his studies. Insulin
sensitivity measurements in 200 young
adults with normal weight and glycemia
showed that insulin-resistant offspring of
diabetic parents had reduced muscle
non–oxidative glucose disposal, reﬂect-
ing increased intramuscular cytoplasmic
lipid, presumably with increased DAG
(4). Shulman hypothesized this to be due
to mitochondrial abnormalities, given
thatATPsynthesiswasreduced,andthere
was evidence of decreased mitochondrial
density in these individuals (5). Insulin
resistance,then,has“manydifferentways
to get there” including diet/lack of activi-
ty–related obesity, genetic abnormalities,
age, and inherited defects in mitochon-
drial metabolism—all of which may be
associated with intracellular fat accumu-
lation in liver and muscle leading to insu-
lin resistance. The metabolic syndrome
studies, which Shulman discussed, show
decreased muscle glycogen synthesis, de-
creased peripheral glucose uptake, and
increased liver triglyceride content with
doubling of de novo hepatic lipogenesis
that leads to atherogenic dyslipidemia,
suggesting similarity to diabetes.
Adipocyte and insulin resistance
Gerald Reaven (Stanford, CA) reviewed
aspects of the relationship between obe-
sity and insulin sensitivity. Using the
steady-state plasma glucose (SSPG) after
infusionofsomatostatin,insulin,andglu-
cose as a measure of insulin resistance,
there is a sixfold variation from the most
insulin-sensitive to the most insulin-
resistant decile in the apparently healthy
nondiabetic population. He mentioned a
study of 300 people in whom the cor-
relation coefﬁcient of BMI versus SSPG
was 0.46, which he interpreted as indica-
tive of “enormous variability at any level
ofBMI.”Obesityisassociatedwithseden-
tary lifestyle, and he then mentioned an-
other study with a somewhat stronger
correlationof0.63betweenclampinsulin
sensitivity and VO2max during exercise.
In Pima and Caucasian subjects, obe-
sity showed a negative relationship with
insulin action up to 28% body fat, with
furtherdegreesofobesitynotsigniﬁcantly
changing insulin sensitivity (6). In both
groups, VO2max was linearly related to in-
sulin action, independently of the degree
of obesity, with the two factors together
accounting for approximately half the
variation in insulin sensitivity. Reaven
suggested that the other half must be ge-
netic. Family studies of Pima Indians, for
example, show a strong inherited compo-
nent.Similareffectshavebeenreportedin
a number of ethnic groups, with a very
high degree of insulin resistance among
Asian Indians. It is the insulin resistance
that appears to convey abnormalities
rather than obesity per se; with compari-
son of nonobese hyperinsulinemic with
normoinsulinemic individuals and obese
hyperinsulinemic with normoinsuline-
mic individuals with similar levels of ac-
tivity, high triglyceride and low HDL
cholesterollevelsareseeninbothinsulin-
resistant groups. Comparing insulin sen-
sitivity tertiles, the upper tertile has much
greater levels of hypertension and new
CVD. In studies of CVD risk factors
among obese subjects according to SSPG
tertile, all risk factors (including C-reac-
tive protein) other than LDL cholesterol
are affected by insulin resistance. Weight
is associated with higher LDL cholesterol
levels, not related to insulin sensitivity,
whereas for triglyceride and HDL choles-
terol and for glycemia, both insulin resis-
tance and BMI interact in effect. Reaven
pointed out that obesity also reduces in-
sulin clearance, further increasing the
insulin response. A U.S. population epi-
demiologicaldatabaseanalysisofage-and
sex-standardized prevalence of cardiom-
etabolic abnormalities by body size and
race/ethnicity showed that a substantial
number of normal-weight individuals ex-
hibit the abnormalities of insulin resis-
tance, while a substantial number of
obese subjects have normal cardiometa-
bolic parameters (7). Addressing the use
of waist circumference or BMI, there is, of
course, a strong correlation between the
two measures (8), and changes in either
lead to change in SSPG; however, among
subjects with either normal waist or in-
creased waist circumference, the degree
of insulin resistance progressively in-
creases with increasing BMI. A recent
study of 168,000 subjects in 63 countries
showed that for 1-SD increase in waist
circumferenceandBMI,theprevalenceof
CVD increased by 36 and 32%, respec-
tively, with similar effects on diabetes (9),
suggesting that either can be used and
that both are important although similar
measures, with the two “highly correlated
and provid[ing] essentially the same in-
formation concerning insulin sensitivity
andCVDriskfactors.”Reavenexpresseda
degree of caution about the concept of a
“metabolic syndrome,” showing evidence
from the Framingham study that having
tworatherthanthreeoftheﬁvediagnostic
abnormalities led to a similar degree of
increase in cardiovascular risk (10). Of
the ﬁve National Cholesterol Education
Program Adult Treatment Panel III diag-
nostic criteria, however, the only one not
independently related to stroke or coro-
nary disease risk is waist circumference
(11), and Reaven pointed out that the
pronounced ethnic variability in normal
waistcircumferencemakesitalesssturdy
measure; one-third of a group of subjects
in Singapore with metabolic syndrome,
for example, had normal waist circumfer-
ence. This has led some to recommend a
change in the criteria for the syndrome
(12), although Reaven commented that
thisdoesnotseemtobesecurelybasedon
clinical studies.
Richard Bergman (Los Angeles, CA)
discussed the pathological basis of and
potential therapies for the insulin resis-
tance syndrome. There is a strong rela-
tionship between insulin sensitivity and
central adiposity (13), more than for
other fat depots, which has not been fully
elucidated yet. Furthermore, Bergman
noted that it also has not been fully clari-
ﬁed why insulin resistance causes hyper-
insulinemia because “we do not really
knowhowthe-cellupregulatesitsfunc-
tion.” He deﬁned the metabolic syn-
drome, from a pathophysiological
perspective, as visceral and subcutaneous
adiposity associated with hepatic and pe-
ripheral insulin resistance, with elevated
FFA, adipokines, and hyperinsulinemia.
Bergman pointed out that the pattern
of obesity in dogs is similar to that in hu-
mans, with most fat in the trunk, so that
magnetic resonance imaging allows accu-
rate visceral and subcutaneous fat mea-
surement, and portal venous sampling
and infusions can be readily carried out.
With high-fat diet leading to modest
weight gain but doubling of both subcu-
taneous and omental fat, the two com-
partments are similar in size (in contrast
to the ratio in humans), although the de-
gree of weight gain and the ratio of omen-
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animaltoanimal.Afterthehigh-fatdiet,
hepatic fat increases and small adipo-
cytes are seen, particularly in omental
fat.Isoproterenol-stimulatedlipolysisis
considerably greater in omental than in
subcutaneous fat, suggesting greater sen-
sitivity to sympathetic nervous system
(SNS) adrenergic stimulation. Genes re-
sponsible for release of fatty acids from
the visceral depot, for hepatic gluconeo-
genesis, and for fat handling are upregu-
lated by overfeeding (14). Release of fatty
acids from the visceral fat depot is cyclic
with a period of 11 min in dogs, as in
humans, with the oscillations suppressed
by 3 blockade, implying a role of the
SNS (15). Pulsatile FFA release causes
hepatic insulin resistance, a mechanism
by which the SNS controls insulin sen-
sitivity, and Bergman suggested that
FFAsratherthanadipokinesarethema-
jor adipocyte-derived cause of insulin
resistance.
Given the much greater effect of mes-
enteric than subcutaneous fat on insulin
sensitivity, as demonstrated by the
marked improvement with omentectomy
in his studies, and the hypothesis that
FFA determines insulin sensitivity, he
studied nocturnal FFA release in the ca-
nine model, as particularly seen on a
high-fat diet, measuring arterial-portal
venous FFA differences. These further
suggestarelationshipofvisceraladiposity
to the pathogenesis of insulin resistance.
He showed evidence of prevention of fat
accumulation and insulin resistance with
the cannabinoid-1 antagonist rimon-
abant, with restoration of the initial fat
deposition pattern, prevention of hepatic
fat accumulation, and elevations in adi-
ponectin levels, not accounted for by
changes in food intake, suggesting a pe-
ripheral effect.
Samuel Cushman (Bethesda, MD)
discussedevidencethatdysfunctionalad-
ipogenesisplaysaroleinthedevelopment
of insulin resistance, with similar conse-
quences of excess adipose tissue in the
context of limited expansibility and li-
poatrophy. Adipose tissue acts as a site of
energy storage, for energy production,
andinsecretionofcirculatingfactorssuch
as leptin, resistin, interleukin 6, tumor
necrosis factor-, and adiponectin. Mod-
els with adipocyte-selective deletion of
GLUT4 expression have impaired insulin
actioninskeletalmuscleasaconsequence
bothofincreasedlevelsofadipocytokines
and of ectopic fat within muscle, associ-
ated with decreased phosphatidylinositol
3-kinase activity.
Adipose tissue develops in a complex
fashion from stem cells that differentiate
into chondroblasts, osteoblasts, myo-
blasts, or preadipocytes, with subsequent
peroxisome proliferator–activated recep-
tor(PPAR)-mediateddifferentiationinto
adipocytes. Adipocyte cell size histogram
analysis reveals a substantial subset of
smaller and larger adipocytes, with the
former possibly representing preadipo-
cytes or other cell types. Compared with
subjects with elevated BMI who are insu-
lin sensitive, those who are insulin resis-
tanthavesmalleradipocyteswithreduced
expression of sterol regulatory element–
binding protein-1c and PPAR, compati-
ble with lack of expansibility, and a lesser
capacity to store fat (16). In an obesity-
prone rat strain, loss of large fat cells de-
velops over a 12-week period on a high-
fat diet, with the greater fat mass
comprised of larger numbers of smaller
adipocytes. In a 12-week human study of
obese insulin-resistant nondiabetic sub-
jects receiving pioglitazone, weight in-
creased; however, there was a signiﬁcant
decrease in visceral fat. Adipocyte size
histograms showed an increase in large
anddecreaseinsmallcells—theratiocor-
relating with the degree of improvement
in insulin action.
Tracy McLaughlin (Stanford, CA)
continued the discussion with a presenta-
tion of the clinical relationships between
obesity and insulin resistance. Eighty-ﬁve
percentofglucosedisposaloccursinskel-
etal muscle; as BMI increases, the insulin
sensitivity decreases, although with a
great degree of variability, so that among
people with BMI 30–34.9 kg/m
2, 55%
are in the most insulin-resistant and 12%
in the most insulin-sensitive tertile, while
among those with BMI 25–29.9 kg/m
2,
44% are in the most insulin-resistant and
25% in the most insulin-sensitive tertile.
Reduction in body weight improves insu-
lin sensitivity (17), and this appears to be
sustained and even to improve over a
3-year period, with attendant improve-
ment in dyslipidemia (18). Insulin sensi-
tivityimproveswithdietaryweightlossin
insulin-resistant but not insulin-sensitive
women (19).
A number of theories have been pro-
posed that explain the relationship of ex-
cess adipose tissue to insulin resistance,
suggestingittobemediatedbychangesin
distribution of fat, adipocytokines, and
inﬂammation or by the development of
ectopicfatstores.Upperbodyfatcontrib-
utes 70% of circulating FFA (20). Basal
lipolysis is greater in subcutaneous than
in omental tissue and is proportional to
fat cell size (21). Catecholamines have
greater effect in stimulating lipolysis, and
insulin has a lesser effect in suppressing
lipolysis, in omental than in subcutane-
ous fat. The visceral adiposity portal con-
ceptisthatdirectFFAdeliverytotheliver
increases production of VLDL and glu-
cose and decreases insulin clearance,
whereas elevation in systemic FFA levels
decreases skeletal muscle glucose uptake
and stimulates hepatic inﬂammation.
Only 15% of FFA comes from visceral fat,
however, and increased hepatic glucose
and VLDL production are likely conse-
quences rather than causes of insulin re-
sistance. Visceral fat does not, according
to McLaughlin, show clear correlation
with insulin sensitivity, and interventions
that improve insulin sensitivity do not
consistently decrease circulating FFA and
typically decrease both visceral and sub-
cutaneous fat. Although adiponectin lev-
els are on average higher in insulin-
sensitive than in insulin-resistant
individuals, again there is a great deal of
variability(22),andalthoughadiponectin
is increased by thiazolidinediones,
McLaughlin stated that her studies have
not clearly shown increases with weight
loss.
Inﬂammatory markers are increased
in proportion to obesity, and there is
some evidence of improvement in insulin
sensitivitywithanti-inﬂammatoryagents.
When equally obese insulin-sensitive and
-resistant individuals are compared be-
foreandafterweightloss,theformerhave
lowerC-reactiveproteinlevelsthatdonot
change, whereas levels are higher in the
latter group and decrease with weight
loss, although not to the level in the insu-
lin-sensitiveindividuals(23).Adiposetis-
sue macrophage numbers increase with
increasing BMI (24), with some sugges-
tion that adipocyte apoptosis causes in-
ﬂammation (25). In periumbilical
subcutaneous fat biopsy of moderately
obese subjects, there was signiﬁcant in-
crease in inﬂammatory gene expression,
but macrophage inﬁltration did not show
strong association with insulin resistance,
so the role of inﬂammation remains to be
elucidated (26).
An interesting question is whether fat
storagecapacity(eitherbyhypertrophyor
hyperplasia) determines whether ectopic
fat develops. Adipocyte enlargement is
limited; an overfeeding study in Pima In-
dians showed 3-kg weight gain but a re-
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50–100%increaseinthenumberofsmall
cells (27). McLaughlin found that peak
adipocyte diameter increases as BMI in-
creasesfrom30to35kg/m
2,withoutsub-
sequent change as weight increases
further, with the ratio of small to large
cells appearing more strongly associated
with weight gain, suggesting failure of ex-
pansion of adipocyte reserves. In this
view, increase in caloric load necessi-
tates increased fat storage with adipo-
cytes unable to enlarge indeﬁnitely,
withoverfeedingcausingrecruitmentof
small cells and thiazolidinediones ap-
pearing to act by increasing adipocyte
mass. Although insulin resistance is as-
sociated with small adipocytes, there is
evidence that pioglitazone increases the
number of small adipocytes, suggesting
multiple possible mechanisms of the re-
lationship between adipocytes and in-
sulin sensitivity.
Antonio Vidal-Puig (Cambridge,
U.K.) discussed adipose tissue expand-
ability, lipotoxicity, and pharmacological
targets based on these concepts. Adipose
tissue should be considered as part of an
integrated system designed to prevent
negative energy balance, in which de-
creased food intake is associated with de-
creased energy expenditure to avoid
weight loss, while energy expenditure
may increase in the setting of adipose tis-
sue expansion. There is epidemiological
evidence of a strong link between obesity
and diabetes (28), and an individual per-
son’s insulin sensitivity decreases as fat
mass increases. Obesity leads, of course,
to a variety of mechanical and psycholog-
ical issues but should be considered in
essenceamismatchbetweenenergyavail-
ability and storage capacity leading to li-
potoxicity with the metabolic syndrome
of fatty liver, diabetes, heart failure, hy-
pertension, dyslipidemia, and a variety of
other consequences. Lipotoxicity may,
then, be considered a state of inappropri-
ate lipid storage in nonadipose tissues,
thus causing insulin resistance. This for-
mulation suggests that improving lipid
storage in adipose tissue will be protec-
tive, whereas in the event of lipid not be-
ingappropriatelystoredinadiposetissue,
activation of mitochondrial fatty acid ox-
idation will have a protective effect. The
adipose tissue expandability hypothesis
suggests that there are limits to the capac-
ity to expand fat mass to store lipid and
that at the point of maximal expansion
lipotoxicity ensues (29). Adipose tissue
expandability is genetically determined
by the number of preadipocytes, dipo-
genesis, vasculogenesis, and dysfunction
of other cellular components in adipose
tissue. There may be a relatively ﬁxed
number of adipocytes, perhaps geneti-
cally determined (30). This concept is il-
lustratedbyrodentlipodystrophymodels
that show the extreme of impaired adi-
pose tissue expandability. Another exam-
ple, based on studies by Vidal-Puig, is of
mice with dominant negative PPAR mu-
tation that unexpectedly show normal
amounts of adipose tissue and are insulin
sensitive. When these mice lack leptin,
however, although they are less obese
than ob/ob animals, they are more insulin
resistant(31).Theadiposetissueexpand-
ability hypothesis suggests conversely
that it should be possible to have extreme
degrees of obesity without metabolic
complications—a ﬁnding exhibited in
ob/ob mice with increased expression of
adiponectin(32).Suchconceptshavehu-
man relevance, in subjects with lipodys-
trophy (33) but also in subjects with
severe obesity but without metabolic syn-
drome (34).
Vidal-Puig noted that abnormal pro-
duction of adipocytokines with increases
in adipose tissue inﬂammation remains
possible with the adipose tissue expand-
ability hypothesis and that as 70% of fat
delivered to the liver is not viscerally de-
rived. Failure of subcutaneous adipose
tissue to expand would also be predicted
to lead to insulin resistance. Adipose tis-
sue expandability implies the existence of
metabolic set points. Once individuals
reach their maximal adipose tissue mass,
metabolic complications ensue, suggest-
ing that pharmacological agents increas-
ingadiposetissueexpandabilitywouldbe
beneﬁcial, allowing treatment of NASH,
diabetes, and dyslipidemia. Identiﬁcation
of organ-speciﬁc lipid networks may pro-
vide key information for speciﬁc treat-
ments, and speciﬁc lipotoxicity patterns
may be useful as biomarkers of CVD and
metabolic risk.
Gut hormones, -cells, and insulin
resistance
Vivian Fonseca (New Orleans, LA) dis-
cussed the need for basic research to bet-
ter understand the mechanisms of
glucagon-like peptide-1 (GLP-1) effect
and noted that the peptide may directly
suppress FFAs. He also pointed out that
GLP-1(9–36) amide, the production of
which is decreased by dipeptidyl pepti-
dase-4 inhibitors, does not affect glucose
metabolism but may have vascular effects
and that glucose-dependent insulino-
tropic peptide has not yet been well stud-
ied for vascular actions. The possibility
that GLP-1 may improve insulin sensitiv-
ity is difﬁcult to assess, given the weight
loss associated with the agent. Glucagon
suppression, which occurs in the post-
prandial state, clearly improves insulin
action. The dipeptidyl peptidase-4 inhib-
itor vildagliptin appears to reduce fat mo-
bilization, suggesting decreased ectopic
fat, which also might be expected to im-
prove insulin sensitivity, and there is evi-
dence that the agent also reduces
postprandial triglyceride, with particular
effect on chylomicrons (35), potentially
improving endothelial function. A
6-week GLP-1 infusion in type 2 diabetic
patients reduced food intake (36), and
GLP-1 analogs act similarly, as shown in
studies of the extended release form of
exenatide (37). A 3-year follow-up of ex-
enatide showed weight loss, increased
HDL and decreased LDL cholesterol lev-
els, and decreased blood pressure, with a
dose-response relationship between
weight loss and the reduction in triglyc-
eride and increase in HDL cholesterol.
Another GLP-1 receptor activator, lira-
glutide, decreased weight in a dose-
dependent fashion, with particular
reduction in visceral rather than subcuta-
neous fat. Over 14 weeks, weight de-
creased by 3 kg, with reduction in blood
pressure by 3–5 mmHg and in triglycer-
ide and cytokine levels. GLP-1 improves
left ventricular function and systolic wall
motion abnormalities following acute
myocardial infarction and angioplasty in
diabetic and also in nondiabetic patients
(38).
There is fascinating information on
vasculareffectsofGLP-1.GLP-1iscardio-
protective in an ischemia-reperfusion
model (39). Fonseca cited a study show-
ing that human coronary artery endothe-
lial cells express the GLP-1 receptor and
reviewedevidencethatglyburide,butnot
glimepiride, reduces a beneﬁcial effect of
GLP-1 on endothelial function (40). Both
GLP-1(7–36) and (9–36) improved left
ventricular function in a cardiomyopathy
model (41), and there is evidence that
both increase nitric oxide synthase activ-
ity, with the (9–36) peptide possibly not
acting via the GLP-1 receptor and with
exenatide not showing such effect (42).
In a Zucker fatty rat model of intimal
hyperplasia following balloon catheter
carotid artery injury, the degree of inti-
mal hyperplasia with insulin resistance
and early diabetes was markedly re-
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to the effects of thiazolidinediones and
statins.
Peter Butler (Los Angeles, CA) dis-
cussed -cell adaptation or maladapta-
tion to obesity and its reversal by gastric
bypass surgery. Approximately 80% of
subjects with morbid obesity have a ﬁve-
fold or greater increase in insulin secre-
tion to maintain normoglycemia despite
severe insulin resistance. Some type 2 di-
abetic patients with morbid obesity have
much more rapid resolution of diabetes
after bariatric surgery than can be ex-
plained by early weight loss, and some
individuals develop severe postprandial
hypoglycemia after the procedure, both
suggesting improvement in insulin secre-
tion. In an autopsy study, nondiabetic
subjects have a 50% increase in -cells
with obesity with increased -cell num-
ber rather than size (43). Interestingly,
this is much more exaggerated in rodents
whohavea10-foldincreasein-cellmass
with obesity, suggesting this not to be an
ideal model for human -cell abnormali-
ties.Pancreasfatvolumecanbemeasured
using computed tomography scan, with
similarrelationshiptoBMIindiabeticand
nondiabetic subjects, with no evidence
that excess pancreatic fat is the cause of
-celldysfunctionintype2diabetes(44).
There are fewer -cells in the pancreas of
people with type 2 diabetes, and there is
increased pancreatic amylin, with pathol-
ogy similar to that in the brain, leading
Butler to question whether this is a con-
sequence of diabetes or a cause. In au-
topsy studies, obese nondiabetic subjects
showawiderangeof-cellvolume,rang-
ing from 1 to 8% of pancreatic mass, with
-cellmassreducedby50%onaveragein
subjects who had impaired fasting glu-
cose and reduced by 65% on average in
thosewhohadtype2diabetesonnotreat-
ment, suggesting that reduction in -cell
mass by half “is an important break-
point” for development of diabetes. Al-
though there is no consensus on the
mechanism of -cell loss in type 2 diabe-
tes, amyloid appears to be an important
mediator, perhaps causing the increased
-cell apoptosis in type 2 diabetic pa-
tients.Butlerpointedoutthat-cellspro-
duce insulin at an extremely high rate,
perhaps leading to amyloid oligomer for-
mation, which causes apoptosis via endo-
plasmic reticulum stress in a fashion
similar to that in Alzheimer’s disease, in-
volving the unfolded protein response
transcription factor CCAAT/enhancer-
binding protein/homologous protein.
Butler made several controversial as-
sertions at the conclusion of his lecture.
Addressing the question of a change in
-cell mass after gastric bypass surgery,
he criticized the study suggesting that
some cases of bariatric surgery are com-
plicatedbynesidioblastosis,causingpost-
prandial hypoglycemia (45). He stated
that the study was not properly carried
out to give a real measurement of -cell
mass, reanalyzed the pathology of the
pancreases from these patients compared
with 16 lean and 31 obese nondiabetic
control subjects, and found no difference
in -cell mass or in insulin-positive cells
in or around pancreatic ducts, suggesting
that postprandial hypoglycemia after gas-
tricbypasssurgeryisduetoinappropriate
insulin secretion rather than increased
-cell number, perhaps related to abnor-
mal regulation of the -cells of some
individuals who had sustained hyperin-
sulinemia for the many years during
which they were obese. He presented re-
sults of a study showing that -cell mass
increasesfrom0.2to0.8gfrombirthto
age 5 years, with average -cell mass sub-
sequently stable for the remainder of life,
although with fairly marked variability
(46).Hepointedoutthatstudiesshowing
that GLP-1 increases -cell mass were
carried out in neonatal mice and stated
that his group showed that the peptide
does not affect -cell mass subsequently,
although this is certainly a topic about
which there is disagreement.
Dan Porte (Seattle, WA) discussed
central control of body weight. In a study
carried out more than 3 decades ago, of
groups of rats after periods of over- and
underfeeding, resulting in greater or
lesser weight gain in comparison with ad
libitum fed animals, the overfed rats lost
andtheleanratsgainedweighttoadegree
directly proportional to basal insulin lev-
els, with all groups eventuating at the
same weight, suggesting that body weight
is regulated by insulin levels (47). Intrac-
erebroventribular insulin infusion low-
ered weight in baboons, with subsequent
regain, while animals not expressing in-
sulin receptors in the brain develop obe-
sity(48),supportingthishypothesis(49).
Leptin acts in a similar fashion (50), sug-
gesting a complementary set of signals
giving extended time scale controls of
body weight. The two signals, leptin and
insulin,actbyincreasingproopiomelano-
cortin and decreasing agouti-related pep-
tide (AgRP)/neuropeptide Y (NPY)
neuronal activity. Endothelial cell insulin
and leptin receptors in localized areas of
the blood brain barrier allow these pep-
tides to be taken up to regulate caloric
balance. A separate gut peptide–based
system acts on day-to-day and meal-to-
meal control of caloric balance, with re-
ceptors on the vagus for cholecystokinin,
bombesin,neuromedinB,GLP-1,peptide
YY (PYY), amylin, glucagon, apolipopro-
tein A-IV, enterostatin, and somatosta-
tin—all of which reduce food intake.
Ghrelin,incontrast,increasesfoodintake
(51).
These systems may be perturbed in
obesity. Leptin resistance has been dem-
onstratedtooccurwithobesity.Although
intranasal insulin, which may be trans-
ported via olfactory neurons, reduces
bodyfatwhenadministeredoveraperiod
of months (52), there is central insulin
resistance in obesity, so it would not ap-
pear to be effective given alone as an obe-
sity treatment. Interestingly, although
subthreshold leptin had no effect alone,
when administered with exendin-4 there
appeared to be additive effect (53). As
weight gain occurs, then, the gut peptide
signalmay becomemoreimportant,and
there is a similar study showing a sub-
therapeutic dose of insulin to produce
satiety when administered with chole-
cystokinin (54).
David Heber (Los Angeles, CA) dis-
cussed obesity, insulin, and the gut-brain
axis and addressed effects of insulin and
leptin resistance. There have been a num-
ber of important discoveries over the past
15 years, including those of the adipocyte
hormones leptin and adiponectin, the
gastrointestinal hormones ghrelin and
GLP-1, and many brain hormones and
transmitters, including NPY, AgRP, mela-
nin-concentrating hormone, endocan-
nabinoids, -melanocyte–stimulating
hormone, cocaine- and amphetamine-
regulated transcript, corticotrophin-
releasing hormone, thyrotropin-releasing
hormone, and serotonin. Multiple brain
areas involved in food intake, with the
hypothalamus best studied, and concepts
ofrewardsignalingandnon–homeostatic
food intake with its relationship to emo-
tional eating are being studied. There are
two long-term satiety signals indicating
nutrient availability, leptin and insulin,
while short-term satiety signals princi-
pally arise from the gastrointestinal
tract, including PYY, cholecystokinin,
and GLP-1, with brain-gut messaging
principallyoccurringviatheSNS.Ther-
mogenesis regulation by brown adipose
tissue may also play a role in energy
balance.
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fect of leptin. Leptin appears to play its
major role in signaling and survival in
times of food deprivation, and the princi-
pal effect of leptin appears to be an in-
crease in food intake occurring when
leptin levels fall—one of many hypotha-
lamic circuits related to food intake. An
individual who was previously obese,
then, has a lower metabolic rate than the
never-obese person in part mediated by
reduction in leptin levels. Leptin resis-
tance may have teleological beneﬁts in
preventing inappropriate reduction in
food intake, although being counterpro-
ductive in the current environment. Vis-
ceral fat, a combination of omental and
mesenteric adipose tissue, comprises
20% of fat in men and 5–8% in women.
High body fat levels may be seen in nor-
mal-weight individuals, and approxi-
mately one-third of normal-weight
subjects have low muscle and high fat
mass. Insulin resistance produced by
excess abdominal fat may in part repre-
sent activation of the innate immune
system to prevent weight loss–related
infection. Advantages of insulin resis-
tance include the maintenance of glu-
cose levels between meals allowing
adaptation to malnutrition, while not
impeding lipogenesis in fat cells, so that
fat storage can occur.
Cholecystokinin inhibits food intake
with maximal effect within 30 min, while
GLP-1—the most potent incretin—also
inhibits food intake, although it is not
clear whether this occurs at physiological
levels. Ghrelin, identiﬁed in 1999, is syn-
thesized by gastric epithelium and in-
creases food intake when administered
either peripherally or centrally, acting to
signal premeal hunger, with levels tend-
ingtobelowinobesity.PYY(3–36)inhib-
its food intake markedly, but daily
ﬂuctuations in endogenous PYY do not
appear to be related to changes in appe-
tite. The effect of bariatric surgery may
involve reduction in ghrelin or increases
in PYY levels. Central regulation of food
intake occurs to a large extent in the ar-
cuate nucleus of the hypothalamus,
which also regulates reproductive func-
tion. The paraventricular nucleus, releas-
ing corticotrophin-releasing hormone
and thyrotropin-releasing hormone, is
another site of food intake regulation.
NPY stimulates appetite, with central ad-
ministrationcausingsustainedhyperpha-
gia,andalsoappearstoincreasecalmness,
with antagonists causing anxiety/stress
symptoms. AgRP increases food intake
through antagonism of the melanocor-
tin-3 and -4 receptors, blocking in-
hibition of food intake caused by -
melanocyte–stimulating hormone, which
is derived from brain proopiomelanocor-
tin. PYY(3–36) acts directly to inhibit
orexigenic NPY neurons. Thus, low lep-
tin, insulin, and PYY(3–36) and high gh-
relin appear to be physiological factors
increasing food intake. Emotional eating,
learned and probably preprogrammed
behaviors, and frontal cortex reward cir-
cuits are, according to Heber, “very hard
circuitstounwire,”withdietandphysical
exerciseas“thedifﬁcultbutmosteffective
means of working against” these biologi-
cal systems.
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